Overview
Immunotherapy has revolutionized the management of non-small cell lung cancer, first in advanced disease settings, and more recently in early-stage disease. Neoadjuvant, adjuvant, and perioperative immunotherapy are now available treatment options for patients with resectable disease. However, the optimal use of these agents remains unclear, necessitating multidisciplinary communication to acquire critical information about the patient’s cancer before making a treatment decision.
This live, virtual webcast is designed to update clinicians involved in the management of NSCLC on the use of immunotherapy for early-stage disease. In particular, the role of molecular testing as it relates to predicting potential benefit from immunotherapy will be a main topic of focus, with emphasis from the faculty panel on potential biomarkers that may help identify optimal therapies along the treatment journey.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Examine crucial biomarkers and patient-specific factors that correlate with immunotherapy response in patients with NSCLC.
- Identify effective approaches to assess and predict response in patients with NSCLC receiving immunotherapy-based regimens.
- Determine the clinical ramifications of key biomarkers and the latest trial evidence in guiding personalized treatment plans for patients with NSCLC.
- Assess recent clinical evidence from studies evaluating current and investigational immunotherapy-based treatment in patients with NSCLC.
Target Audience
This educational program is directed toward pathologists and medical oncologists who diagnose or treat patients with solid tumors. Nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment and management of solid tumors will also be invited to participate in the activity.
Melissa Johnson, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Chair, Cancer Committee
TriStar Centennial Medical Center
Nashville, TN
Edward Garon, MD, MS
Professor, Department of Medicine, Hematology/Oncology
Director, Thoracic Oncology Program
Co-Director, Signal Transduction and Therapeutics
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Solange Peters, MD, PhD
Full professor, University of Lausanne|
Chair, Medical Oncology, Thoracic Malignancies Program
Department of Oncology
University Hospital of Lausanne
Lausanne, Switzerland
Ignacio I. Wistuba, MD
Professor and Chair, Department of Translational Molecular Pathology
Professor, Department of Thoracic/Head and Neck Medical Oncology
Codirector, Division of Pathology/Laboratory Medicine
The University of Texas MD Anderson Cancer Center
Faculty, University of Texas Graduate School of Biomedical Sciences
Houston, TX
Revolutionizing NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies | ||
Time | Title | Faculty |
11:30 AM | Welcome and Introduction | Melissa Johnson, MD |
11:35 AM | The Front Lines: Effectively Utilizing Biomarkers to Predict Optimal NSCLC Management Immunotherapy | Ignacio I. Wistuba, MD |
12:00 PM | Recent Evidence of Immunotherapies in Resectable NSCLC | Solange Peters, MD, PhD |
12:20 PM | Determining the Role of Immunotherapy in Patients Unresectable NSCLC | Melissa Johnson, MD |
12:40 PM | Where Immune Checkpoint Inhibition Fits in the Treatment Paradigm of Metastatic NSCLC | Edward Garon, MD, MS |
1:00 PM | Survey, Questions and Answers | Melissa Johnson, MD |
1:10 PM | Concluding Remarks | |
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.